Articles tagged with Tumor Regression
Researchers at Hokkaido University have developed a chimeric anti-PD-L1 antibody that induces immune responses and tumor regression in dogs with malignant cancers. The antibody targets PD-L1-positive cancers, including oral malignant melanoma and undifferentiated sarcoma.
Researchers found that neoadjuvant immunotherapy with nivolumab was safe and did not delay surgery in patients with early-stage non-small-cell lung cancer. Six of 15 patients experienced major pathological regression, suggesting potential activity of anti-PD-1 immunotherapy in early stage lung cancer.
A phase I study of LOXO-101 demonstrated efficacy in reducing tumors in six patients with TRK fusion-positive cancers, including sarcoma, thyroid, and non-small cell lung. The study showed significant tumor regression in all six patients, with one patient experiencing a 17% tumor reduction.
A study examines the safety of propranolol therapy in infants with vascular tumors, finding severe respiratory and cardiac disorders are rare but significant. The treatment has been shown to induce regression, but caution is advised due to potential risks.
Researchers found that altering the p53 gene family causes rapid regression of tumors deficient in or lacking p53. Existing diabetes drugs that impact the same gene-protein pathway might be effective for cancer treatment.
A new approach identified two mutated tumor targets, KIF2C and POLA2, that play important roles in cell proliferation and may stimulate immune responses. This study provides a technical solution to identify mutated tumor targets for adoptive T-cell therapy, which has shown promise in treating metastatic melanoma.
A recent survey found that most people with relevance to HPV vaccination were unaware of its efficacy in preventing cervical cancer. The study suggests encouraging healthcare providers to discuss the vaccine's effectiveness with patients and parents of eligible adolescents to reduce cervical cancer incidence and mortality.
This study analyzed data from over 1.3 million middle-aged women in the UK, finding that moderate alcohol consumption was associated with a lower risk of lymphoid malignancies. Smoking, on the other hand, was linked to an increased risk of these cancers.
A new study by Stanford researchers suggests that a novel mathematical formula can predict the success of certain cancer therapies by tracking the rate of tumor response during the first weeks of treatment. The formula, which uses advanced high-school-level math, identifies oncogene addiction in cancers, allowing for targeted therapies...
Researchers developed a combinatorial approach using viruses to destroy tumors, which was shown to provide substantial regression and cure of tumors in mice. By targeting tumor blood vessels, this approach could potentially treat a wide range of cancers, offering new hope for cancer treatment.
Researchers at Weizmann Institute discovered a new protein partnership between TrkA and CCM2 that leads to pediatric tumor regression. This finding may lead to the development of drugs that induce tumor regression. The study found that TrkA and CCM2 are always expressed together in tumors with high regression rates.
A study found breast cancer rates increased in women screened every two years compared to those screened once, suggesting some cancers may spontaneously regress. The findings raise concerns about the value of mammography and highlight the need for further research into breast cancer's natural history.
Researchers have identified a new combination therapy that targets tumors with B-RAF mutations by combining MEK inhibitors with BH3 mimetics, showing promise in treating melanomas and other solid tumors.
Researchers found that a disruption of gut bacteria plays a key role in the effectiveness of radiation therapy for cancer. In mice, radiation therapy boosted immune cells' ability to fight tumors, and gut bacteria were crucial to this effect.
Researchers found that increased expression of HO-1 and administration of carbon monoxide protected mice from MS. In contrast, mice lacking HO-1 developed more severe disease. The study suggests modulating HO-1 expression or administering carbon monoxide may be useful therapeutic strategies for treating patients with MS.
Researchers have discovered a new antibody that effectively regresses lung tumors in mice with two types of lung cancer driven by mutant forms of the EGFR protein. The study highlights the potential therapeutic benefits of this antibody, ch806, for treating patients with specific lung cancer mutations.
Researchers found that vaccines inducing intermediate T cell responses effectively protected mice from tumor growth, while those with high responses did not. The study suggests re-evaluating the role of T cell response magnitude in vaccine development.
A pilot study found that folic acid supplementation significantly increased mean folate levels and decreased homocysteine levels, leading to complete resolution of leucoplakia lesions in 28% of patients. The results suggest folate may effectively reduce cancer progression risk, especially in those with hypofolatemia.
Researchers found that imatinib partially regressed lesions and stabilized disease in patients with AIDS-related Kaposi's sarcoma. However, high toxicity was observed due to medication interactions, highlighting the need for optimized dosing schedules.
A US study found that most low-grade cervical lesions (LSIL) in young women will regress spontaneously, lending support for monitoring these cytological lesions. Follow-up HPV status was a strong predictor of regression, but persistent multiple HPV types slowed rates of regression.
A study by Johns Hopkins Bloomberg School of Public Health found that Highly Active Antiretroviral Therapy (HAART) improved the regression rates of cervical squamous intraepithelial lesions (SIL) in HIV-positive women. However, a significant proportion of high-risk lesions persisted even among those who received HAART.
Researchers have created a colony of mice that can fight off aggressive cancer cells, shedding light on a previously unrecognized mechanism of host resistance. The discovery may hold promise for developing better therapies or prevention methods against cancer in humans.
The study reveals key mechanisms and pathways involved in immune response regulation. It highlights the importance of understanding immunological functions to develop new therapeutic approaches.
Researchers suggest a new approach to managing abnormal cervical smears, recommending a 'wait and see' period of at least 6 months for women infected with high-risk human papillomavirus. This strategy aims to prevent overtreatment by allowing the virus to clear before further action is taken.